業績|論文・出版物|目次|ALL
ヒト肝臓オルガノイド由来肝細胞の開発と創薬応用
仝嫣然、植山(鳥羽)由希子、水口裕之
PHARM STAGE (in press)
Considerations for developing CYP induction assays in hepatocytes: Insights from a multilaboratory study.
Toyoda H., Nozue A., Nishida Y., Yakabe Y., Aiki Y., Ueyama-Toba Y., Takayama K., Mizuguchi H., Mori C., Torisawa Y.S., Sakai Y., Iwao T., Matsunaga T., Horiuchi S., Yamazaki D., Ishida S., Kojima N., Inamura K., Sakai Y., Nishikawa M., Mihara I., Akabane T., Ito Y.
Eur. J. Cell Biol., 104, 151497 (2025)
An in vitro safety evaluation model for assessing the effects of a chemical drug on the human intestinal barrier integrity using genetically modified Caco-2 cells expressing drug-metabolizing enzymes.
Bai L., Sakimura S., Niwa Y., Mizuguchi H., Maeda S., Ikemura K., Okuda M., Kondoh, M.
Toxicol. Lett., 410, 113-120 (2025)
Two-dimensionally cultured functional hepatocytes generated from human induced pluripotent stem cell-derived hepatic organoids for pharmaceutical research.
